Table 3.
Distribution of type of first disease progression by risk-group
| First progression event | Low-risk | Intermediate-risk | High-risk |
|---|---|---|---|
| RTOG-0129* | (n=123) | (n=73) | (n=64) |
| Locoregional | 10 (8.1%) | 14 (19.2%) | 21 (32.8%) |
| Distant (± locoregional) | 10 (8.1%) | 12 (16.4%) | 11 (17.2%) |
| Any | 20 (16.3%) | 26 (35.6%) | 32 (50.0%) |
| RTOG-0522Ω | (n=140) | (n=93) | (n=54) |
| Locoregional | 20 (14.3%) | 11 (11.8%) | 10 (18.5%) |
| Distant (± locoregional) | 9 (6.4%) | 18 (19.4%) | 11 (20.4%) |
| Any | 29 (20.7%) | 29 (31.2%) | 21 (38.9%) |
| Overall£ | (n=263) | (n=166) | (n=118) |
| Locoregional | 30 (11.4%) | 25 (15.1%) | 31 (26.3%) |
| Distant (± locoregional) | 19 (7.2%) | 30 (18.1%) | 22 (18.6%) |
| Any | 49 (18.6%) | 55 (33.1%) | 53 (44.9%) |
Among RTOG-10129 participants with recurrence (e.g. restricting analysis to those who have disease progression), there was no difference in distribution of locoregional vs. distant failures (±locoregional) by risk groups (p=0.48).
Among participants with recurrence in RTOG-0522 (e.g. restricting analysis to those who have disease progression), when considering distribution for type of first failure there was a non-significant increase in locoregional failure in the low-risk group as compared with the intermediate- and high- risk groups (p=0.05).
When considering the distribution of first disease progression among participants with recurrence in the overall study population (RTOG-0129 and RTOG-0522) by risk group there was no difference in distribution of locoregional or distant failures by risk groups (p=0.22).